Advances in immune-based therapies of renal cell carcinoma (Q35987770)

11 August 2017

1 reference

title

Advances in immune-based therapies of renal cell carcinoma (English)

1 reference

11 August 2017

John S Lam

1

1 reference

PubMed ID

15606335

11 August 2017

Arie S Belldegrun

series ordinal

2

1 reference

PubMed ID

15606335

11 August 2017

Robert A Figlin

series ordinal

3

1 reference

11 August 2017

1 December 2004

1 reference

Expert Review of Anticancer Therapy

11 August 2017

1 reference

11 August 2017

4

1 reference

11 August 2017

6

1 reference

11 August 2017

1081-1096

1 reference

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

11 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

IL-2, regulatory T cells, and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Cytokine-based therapy for metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Interaction of retinoic acid and interferon in renal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Haemopoietic stem-cell transplantation: recent progress and future promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

p53 and HER-2 alterations in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: five-year results of a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.6.1081

10.1586/14737140.4.6.1081

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15606335